Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$100.69
neg -0.31
-0.31%
Today's Range: 99.57 - 101.66 | GILD Avg Daily Volume: 13,637,300
Last Update: 03/30/15 - 4:14 PM EDT
Volume: 9,956,475
YTD Performance: 7.15%
Open: $101.12
Previous Close: $101.00
52 Week Range: $63.50 - $116.83
Oustanding Shares: 1,489,401,683
Market Cap: 150,541,275,109
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 12 10 11 12
Moderate Buy 2 2 2 2
Hold 3 3 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.61 1.69 1.65 1.61
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 13.75
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
13.75 13.80 27.26
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.69% 41.44% 326.25%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $3.13 $2.76 $9.89 $9.39
Number of Analysts 1 1 2 2
High Estimate $3.13 $2.76 $10.64 $10.77
Low Estimate $3.13 $2.76 $9.13 $8.00
Prior Year $1.44 $2.32 $7.91 $9.89
Growth Rate (Year over Year) 117.36% 18.97% 24.97% -5.06%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Robert Moreno

 | Mar 30, 2015 | 2:33 PM EDT

Trading guidelines for Goodyear, Gilead and Gap.

By

Jim Cramer

 | Mar 30, 2015 | 5:39 AM EDT

An answer to those asking me what's worth buying.

By

Jim Cramer

 | Mar 27, 2015 | 5:21 AM EDT

If there is no catalyst, I'd join those who sell on a bounce.

By

Jim Cramer

 | Mar 26, 2015 | 5:47 PM EDT

It takes a village of positive reports to sustain market.

By

Bret Jensen

 | Mar 26, 2015 | 9:30 AM EDT

It looks like it could be stormy in the markets today too.

By

Bret Jensen

 | Mar 24, 2015 | 11:00 AM EDT

A strategy to immunize biotech investors from regret.

By

Jim Cramer

 | Mar 21, 2015 | 2:30 PM EDT

Own them, or take something off the table?

By

Jim Cramer

 | Mar 20, 2015 | 10:53 AM EDT

I really like the stocks. But I also like making money on stocks.

By

Bret Jensen

 | Mar 20, 2015 | 7:14 AM EDT
As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami).
By

Gary Morrow

 | Mar 19, 2015 | 4:00 PM EDT

There is now a low-risk entry opportunity for GILD bulls.

Exxon Mobil (XOM) shares are back up near the $85.75 level. This area was solid support fo...
Good closing piece by "El Capitan" on the nature of buyers these days. I totally agree. As...
I have covered my small SPY short that I put on today after the close at about $208.03 for...
The fact that Twitter (TWTR) "bears" had a chance to inflict more serious damage by pressi...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.